Aarti Pharmalabs
AARTIPHARM NSE
Aarti Pharmalabs
HealthcareNSE: AARTIPHARM BSE: 543748 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹7,434 Cr
Volatility
Moderate
P/E Ratio
35.17
EBITDA
₹366 Cr
Return on Equity
13.69%
Debt to Equity
0.35
Book Value
₹234.3
EPS
₹24.86
52W High
₹946.1
52W Low
₹585
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
3- Stock is trading at 3.53 times its book value
- Company has a low return on equity of 11.9% over last 3 years.
- Promoter holding has decreased over last 3 years: -3.12%
Growth Rate
Revenue Growth
-14.39% lower than
3Y
Net Income Growth
-29.97% lower than
3Y
Cash Flow Change
53.25% higher than
3Y
ROE
10.94% lower than
3Y
ROCE
2.38% higher than
3Y
EBITDA Margin (Avg.)
-10.7% lower than
3Y
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 69d agoAI opinion · based on fundamentals
Risk high
Aarti Pharmalabs Ltd is a healthcare company with a market cap of ₹6,378 Cr trading at a PE of 36.7x. The company is experiencing a significant earnings contraction with TTM profit declining 35% and sales declining 14%, while its 3-year stock CAGR of 25% reflects prior momentum that has reversed sharply with a -22% return over the last year.
Bull Case 7
- 3-year stock CAGR of 25% indicates strong medium-term wealth creation for earlier investors despite recent correction
- 5-year average ROE of 13% suggests the business has historically generated reasonable returns on shareholder equity
- 3-year average ROE of 12% remains above cost of equity for most Indian companies, indicating underlying business quality
- Market cap of ₹6,378 Cr provides reasonable scale and liquidity for institutional participation
- Dividend yield of 0.21% shows the company maintains a dividend payout policy despite earnings pressure
- The -22% stock decline in the last 1 year may offer a more attractive entry valuation compared to prior highs for contrarian investors
- Operating in the healthcare/pharma sector which benefits from structural domestic and export demand tailwinds in India
Bear Case 8
- TTM compounded profit growth of -35% indicates severe earnings deterioration in the most recent period
- TTM compounded sales growth of -14% shows meaningful revenue contraction, not just margin compression
- PE ratio of 36.7x is elevated given that earnings are declining, implying the stock is priced for growth that is not materializing
- Last year ROE dropped to 9% from a 3-year average of 12%, showing declining capital efficiency
- Price-to-book of 3.01x is high relative to the low ROE of 11.9% over 3 years, suggesting stretched valuation on asset basis
- 3-year compounded profit growth of -3% indicates earnings stagnation even over a medium-term horizon
- 3-year compounded sales growth of -2% shows the topline has been essentially flat over three years
- Stock has declined 22% over the past year, reflecting sustained negative market sentiment and potential de-rating
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 69d ago Positives 1
- New Tarapur manufacturing block Jun 30
Aarti Pharmalabs inaugurated a new manufacturing block at Tarapur Unit 5, adding 3600 TPA capacity for Xanthine derivatives, bringing total capacity to 9600 TPA.
TL;DR: Aarti Pharmalabs is executing on capacity expansion with a meaningful 60% increase in Xanthine derivatives capacity at Tarapur. No visible headwinds in recent news flow. The trend is constructive as the company invests in growth, though limited news coverage makes it difficult to assess broader operational performance.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 458 | 440 | 449 | 506 | 555 | 458 | 538 | 564 | 386 | 418 | 432 | 583 | 536 |
| Expenses | 373 | 352 | 353 | 388 | 459 | 364 | 409 | 418 | 293 | 344 | 330 | 470 | 400 |
| Operating Profit | 85 | 88 | 96 | 118 | 96 | 94 | 129 | 146 | 93 | 74 | 102 | 113 | 136 |
| OPM % | 19% | 20% | 21% | 23% | 17% | 20% | 24% | 26% | 24% | 18% | 24% | 19% | 25% |
| Other Income | 0 | 1 | 1 | 2 | 2 | 4 | 5 | -2 | 2 | 0 | 2 | 14 | 8 |
| Interest | 4 | 4 | 4 | 5 | 5 | 6 | 10 | 7 | 7 | 11 | 13 | 17 | 13 |
| Depreciation | 17 | 18 | 19 | 19 | 20 | 21 | 23 | 23 | 23 | 25 | 29 | 28 | 30 |
| PBT | 64 | 67 | 74 | 96 | 74 | 72 | 101 | 115 | 65 | 39 | 63 | 82 | 101 |
| Tax % | 26% | 23% | 29% | 32% | 25% | 24% | 26% | 23% | 24% | 28% | 24% | 25% | 25% |
| Net Profit | 47 | 52 | 53 | 65 | 55 | 55 | 74 | 88 | 50 | 28 | 48 | 61 | 76 |
| EPS in Rs | 5.2 | 5.72 | 5.82 | 7.2 | 6.12 | 6.03 | 8.16 | 9.75 | 5.46 | 3.08 | 5.29 | 6.74 | 8.4 |
Profit & Loss
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 0 | 1,200 | 1,945 | 1,853 | 2,115 | 1,819 | 1,969 |
| Expenses | 0 | 993 | 1,603 | 1,467 | 1,651 | 1,450 | 1,543 |
| Operating Profit | 0 | 207 | 342 | 386 | 464 | 369 | 426 |
| OPM % | — | 17% | 18% | 21% | 22% | 20% | 22% |
| Other Income | 0 | 3 | 2 | 5 | 10 | 15 | 23 |
| Interest | 0 | 12 | 21 | 17 | 27 | 47 | 53 |
| Depreciation | 0 | 42 | 63 | 73 | 87 | 104 | 112 |
| PBT | 0 | 155 | 261 | 300 | 361 | 233 | 284 |
| Tax % | — | 21% | 26% | 28% | 24% | 25% | — |
| Net Profit | 0 | 122 | 193 | 217 | 272 | 175 | 213 |
| EPS in Rs | — | — | 21.35 | 23.93 | 30.05 | 19.27 | 23.51 |
| Div. Payout % | — | 0% | 9% | 13% | 17% | 18% | — |
Balance Sheet
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity Capital | 0.25 | 0.25 | 45 | 45 | 45 | 45 |
| Reserves | 0 | 1,386 | 1,513 | 1,712 | 1,945 | 2,079 |
| Borrowings | 0 | 338 | 215 | 285 | 413 | 754 |
| Other Liabilities | 0 | 315 | 470 | 540 | 503 | 603 |
| Total Liabilities | 0 | 2,040 | 2,244 | 2,582 | 2,906 | 3,482 |
| Fixed Assets | 0 | 782 | 926 | 1,033 | 1,137 | 1,525 |
| CWIP | 0 | 187 | 102 | 137 | 374 | 305 |
| Investments | 0 | 32 | 87 | 107 | 77 | 194 |
| Other Assets | 0 | 1,038 | 1,130 | 1,305 | 1,319 | 1,457 |
| Total Assets | 0 | 2,040 | 2,244 | 2,582 | 2,906 | 3,482 |
Cash Flow
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | 0 | -44 | 250 | 216 | 332 | 262 |
| Investing | 0 | -139 | -158 | -215 | -414 | -431 |
| Financing | 0 | 260 | -163 | 10 | 65 | 171 |
| Net Cash Flow | 0 | 78 | -71 | 12 | -17 | 2 |
| Free Cash Flow | 0 | -185 | 130 | 18 | -112 | -186 |
| CFO/OP | — | -11 | 91 | 71 | 85 | 84 |
Ratios
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor Days | — | 115 | 84 | 102 | 99 | 117 |
| Inventory Days | — | 272 | 188 | 230 | 190 | 280 |
| Days Payable | — | 123 | 106 | 135 | 90 | 146 |
| Cash Conversion Cycle | — | 264 | 166 | 197 | 200 | 251 |
| Working Capital Days | — | 111 | 94 | 110 | 105 | 90 |
| ROCE % | — | 19% | 16% | 17% | 17% | 11% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Aarti Pharmalabs insights
67 extracted metrics + investor summaries across FY12–FY26.
Documents
1
Board Meeting Intimation for Approval Of The Audited Financial Results For The Quarter And Financial Year Ended March 31, 2026 And Recommendation Of Final Dividend, If Any.
12h - Board meets May 18, 2026 to approve FY26 audited results and consider final dividend. 12h - Board meets May 18, 2026 to approve FY26 audited results and consider final dividend.
2
Announcement under Regulation 30 (LODR)-Newspaper Publication
7 Apr - Newspaper Advertisement for the Second 100-Day Campaign - "Saksham Niveshak" 7 Apr - Newspaper Advertisement for the Second 100-Day Campaign - "Saksham Niveshak"
3
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Apr - Regulation 74(5) compliance certificate for quarter ended March 31, 2026; no shareholder requests received. 7 Apr - Regulation 74(5) compliance certificate for quarter ended March 31, 2026; no shareholder requests received.
4
Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
4 Apr - Renil Rajendra Gogri created pledge on 15,19,919 Aarti Pharmalabs shares on 25-Mar-26. 4 Apr - Renil Rajendra Gogri created pledge on 15,19,919 Aarti Pharmalabs shares on 25-Mar-26.
Frequently Asked Questions about Aarti Pharmalabs
What does Aarti Pharmalabs Ltd do?
Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals[1]
Where is Aarti Pharmalabs Ltd (AARTIPHARM) listed?
Aarti Pharmalabs Ltd trades as AARTIPHARM on the NSE and under code 543748 on the BSE.
Which sector does Aarti Pharmalabs Ltd belong to?
Aarti Pharmalabs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Aarti Pharmalabs Ltd?
Aarti Pharmalabs Ltd has a market capitalisation of ₹7,434 Cr, which places it in the Mid Cap band.
What is the PE ratio of Aarti Pharmalabs Ltd?
Aarti Pharmalabs Ltd trades at a PE ratio of 35.17, on earnings per share of ₹24.86, against a book value of ₹234.3 per share.
What is the 52-week high and low of Aarti Pharmalabs Ltd?
Over the last 52 weeks Aarti Pharmalabs Ltd has traded between ₹585 and ₹946.1.
Does Aarti Pharmalabs Ltd pay dividends?
Aarti Pharmalabs Ltd has a dividend yield of 0.42%.
What is the Return on Equity (ROE) of Aarti Pharmalabs Ltd?
Aarti Pharmalabs Ltd reported a return on equity of 13.69%. Its debt-to-equity ratio is 0.35.
Company Information
Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals[1]
Website aartipharmalabs.com
CEO Ms. Hetal Gogri Gala
Employees 2,162
Listed 2023-01-30
Face Value ₹ 5
Issued Size 9,06,41,224
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AARTIPHARM.md for Aarti Pharmalabs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.